Quoin Pharmaceuticals Ltd 's Cash & cash equivalent grew by 207.25 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Quoin Pharmaceuticals Ltd 's Quick Ratio to 6.95, above Quoin Pharmaceuticals Ltd average Quick Ratio.

Within Major Pharmaceutical Preparations industry 314 other companies have achieved higher Quick Ratio than Quoin Pharmaceuticals Ltd in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 465 to 1423.

Explain Quick Ratio?
How much Cash & cash equivalents QNRX�s has?
What are QNRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/QNRX/financial-strength

https://api.csimarket.com/api/v1/companies/QNRX/fundamentals

https://api.csimarket.com/api/v1/companies/QNRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

QNRX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-17.16 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	511.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	6.95	Subscribe	Subscribe	Subscribe	Subscribe
QNRX's Total Ranking	# 1423	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-27.79 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	207.25 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 315
Healthcare Sector	# 550
Overall Market	# 1423

Quick Ratio Statistics
High	Average	Low
8.19	3.66	0.94
(Sep 30 2022)		(Sep 30 2025)

Financial Statements
Quoin Pharmaceuticals Ltd 's Current Liabilities	$ 5 Millions	Visit QNRX's Balance sheet
Quoin Pharmaceuticals Ltd 's Cash & cash equivalent	$ 33 Millions	Visit QNRX's Balance sheet
Source of QNRX's Sales		Visit QNRX's Sales by Geography

Cumulative Quoin Pharmaceuticals Ltd 's Quick Ratio

QNRX's Quick Ratio for the trailling 12 Months

QNRX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	16.42 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	97.98 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	3.45	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2000	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-4.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	56.62 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to QNRX Financial Strength Comparisons >> Go to Compare QNRX Quick Ratio to its Competitors

News about Quoin Pharmaceuticals Ltd Quick Ratio

Quoin Pharmaceuticals Pioneering New Frontiers in Rare Disease Therapeutics

Breaking New Ground in Pediatric Netherton Syndrome Quoin Pharmaceuticals Ltd., a prominent player in the niche domain of rare and orphan diseases, is making significant strides in advancing clinical research and therapeutic avenues. Recently, the company announced a critical development in its pediatric Netherton Syndrome (NS) study. The ongoing investigator-led study that is charting new territories has successfully enrolled three additional patients, broadening the scope and robustness of the research. This expansion comes on the heels of an impressive 9-month data update from the very first pediatric participant, showcasing promising outcomes that signal a potential breakthrough in the treatment of NS. Promising Advances in Peeling Skin Syndrome In tandem with its efforts in Netherton Syndrome, Quoin Pharmaceuticals is also garnering attention for its pioneering work in Pediatric Peeling Skin Syndrome. Earlier this year, Quoin unveiled initial positive clinical data from this ongoing study, reinforcing its commitment to tackling rare dermatological conditions. The encouraging findings amplify the potential of Quoin’s therapeutic interventions, offering hope to patients grappling with these debilitating skin conditions.

On the trailing twelve months basis QNRX Cash & cash equivalent more than doubled by 511.01 % in Q3 2026 year on year, while Current Liabilities plummeted to $5 millions, this led to increase in in Quoin Pharmaceuticals Ltd 's Quick Ratio to 3.45, above QNRX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Quoin Pharmaceuticals Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 1787 to 3873.

Explain Quick Ratio?
How much Cash & cash equivalents QNRX�s has?
What are QNRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 437
Healthcare Sector	# 895
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.75	2.5	0.5
(Dec 31 2020)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions
Stablecoin Development Corporation	13.01	$ 7.153 Millions	$ 0.550 Millions
Uniqure N v	12.78	$ 768.430 Millions	$ 60.142 Millions
Rhythm Pharmaceuticals Inc	12.62	$ 320.944 Millions	$ 25.438 Millions
Dyne Therapeutics Inc	12.53	$ 1,134.386 Millions	$ 90.545 Millions
Sensei Biotherapeutics Inc	12.44	$ 174.795 Millions	$ 14.049 Millions
Spyre Therapeutics Inc	12.24	$ 82.727 Millions	$ 6.760 Millions
Edgewise Therapeutics inc	12.10	$ 1,743.893 Millions	$ 144.106 Millions
Structure Therapeutics Inc	11.62	$ 1,244.661 Millions	$ 107.104 Millions
Immunome Inc	11.27	$ 461.582 Millions	$ 40.966 Millions
Korro Bio Inc	11.06	$ 165.015 Millions	$ 14.923 Millions
Xenon Pharmaceuticals Inc	10.99	$ 950.798 Millions	$ 86.487 Millions
Newamsterdam Pharma Company N v	10.99	$ 628.242 Millions	$ 57.154 Millions
Vtv Therapeutics Inc	10.99	$ 77.164 Millions	$ 7.024 Millions

Date modified: 2026-11-08T19:41:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.